The Readout Loud
A podcast by STAT - Thursdays
Categories:
336 Episodes
-
274: Covid’s latest surge, Alnylam at the FDA, & the end of an era
Published: 9/14/2023 -
273: Back to school for biotech, Biogen's potential pivot, & Illumina's next chapter
Published: 9/7/2023 -
272: Vivek's star turn, leaky drug data, & biotech as family business
Published: 8/24/2023 -
271: Racing for gene therapy, a pioneering approval, & startups in the lurch
Published: 8/18/2023 -
270: Your guide to Wegovy’s blockbuster heart study
Published: 8/10/2023 -
269: Biotech layoffs, eye drug drama, & gene therapy milestones
Published: 8/3/2023 -
268: Biogen's sticky situation, Wegovy's risks, & biotech insider trading
Published: 7/27/2023 -
267: BridgeBio's big week, Lilly's Alzheimer's data, & succession at Stanford
Published: 7/20/2023 -
266: Wegovy in the brain, pivotal Alzheimer's data, & pulling Threads
Published: 7/13/2023 -
265: Novavax's CEO promises a turnaround & how Lilly roiled the obesity market
Published: 6/29/2023 -
264: Messy PBM conflicts, debatable vaccines, & the future of flu season
Published: 6/22/2023 -
263: Biogen's messy board, Laronde's data problem, & the downside of a boom
Published: 6/15/2023 -
262: Merck v. USA, the best of ASCO, and Leqembi at the FDA
Published: 6/8/2023 -
261: Fake medical devices, real cancer drugs, & curious Ozempic effects
Published: 6/1/2023 -
260: ChatGPT in medicine, a boom in weight loss pills, & Sarepta at the FDA
Published: 5/25/2023 -
259: The FTC v. Amgen, Sarepta's future, & Galapagos' turnaround
Published: 5/18/2023 -
258: Pharma vs. PBMs, Sarepta at the FDA, & a bold idea gone awry
Published: 5/11/2023 -
257: Lilly's Alzheimer's success, a milestone FDA approval, & Moderna's shrinking business
Published: 5/4/2023 -
256: Explaining the E.U.'s pharma overhaul, Lilly's booming business, & a long-awaited drug approval
Published: 4/27/2023 -
255: Sarepta's pivotal moment, biotech's big week, & the future of Covid boosters
Published: 4/20/2023
STAT’s weekly biotech podcast, breaking down the latest news, digging deep into industry goings-on, and giving you a preview of the week to come.